AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal
AstraZeneca will pay insitro $40 million upfront in a deal worth up to $1.5 billion to apply the AI drug discovery company's platform to MASH and cardiomyopathies.
insitro
Private
Machine-learning-driven drug discovery company that builds predictive models of human disease from large-scale cellular data and patient genetics, then advances the resulting insights into small-molecule and antibody therapeutics.
Company Info
Sector:Biotechnology / AI Drug Discovery
Headquarters:South San Francisco, California, USA
Founded:2018
Website:www.insitro.com/
Funding Round:Series C
Total Funding:~$700M
Funding & Investor Relations
Notable Investors
- Andreessen Horowitz
- GV (Google Ventures)
- Arch Venture Partners
- T. Rowe Price
Upcoming Milestones & Key Dates
2026-10-15
Partnership
Up to $1.5B AI target discovery collaboration with AstraZeneca for MASH and cardiomyopathies ($40M upfront)
Clinical Development Pipeline
CTRO-1013
Target: UndisclosedALS-2
Target: Undisclosed (Bristol Myers Squibb collaboration)OBS-1
Target: UndisclosedRecent News
Leadership Team
Daphne Koller
Founder and Chief Executive Officer